logo-loader

Regenicin reimburses Lonza Walkersville in full

Published: 19:15 21 Jun 2011 BST

no_picture_pai

Regenicin (OTCBB:RGIN) said Tuesday it has reimbursed Lonza Walkersville Inc., a supplier to the biopharmaceuticals market, $0.26 million for the work Lonza did in moving its main product candidate through the FDA application process.

In late April, New Jersey-based Regenicin, which specializes in the development of regenerative cell therapies to restore damaged tissues and organs, received a letter from Lonza alleging the company was in breach of their "know-how license and stock purchase agreement". The letter noted a past due payment of $183,687, which was later increased to $260,344 in June.

Regenicin said that while there was a dispute relating to the amount owed, the company paid the invoice in full to avoid a conflict with what it called "an important contractual partner".

"We look forward to a long and successful relationship in the future with the Lonza team," said Regenicin CEO Randall McCoy, "and we're happy to have this issue behind us as we move forward."

Oriole Resources outlines 2023 achievements and future exploration plans

Oriole Resources PLC (AIM:ORR) CEO Tim Livesey and chief financial officer Bob Smeeton join Proactive's Stephen Gunnion with details of the company's 2023 financial and operational performance. Livesey highlighted successful exploration programs in Cameroon, at the Bibemi and Mbe projects,...

33 minutes ago